Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

NCT03970447 is registered in ClinicalTrials.gov with Global Coalition for Adaptive Research as lead sponsor.

NCT NCT03970447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03970447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Lead sponsor
Global Coalition for Adaptive Research
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 30, 2019
Completion date
June 30, 2030
Enrollment
2,250 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma